Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization.

Senturk S, Shirole NH, Nowak DG, Corbo V, Pal D, Vaughan A, Tuveson DA, Trotman LC, Kinney JB, Sordella R.

Nat Commun. 2017 Feb 22;8:14370. doi: 10.1038/ncomms14370.

2.

The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein.

Chen M, Nowak DG, Narula N, Robinson B, Watrud K, Ambrico A, Herzka TM, Zeeman ME, Minderer M, Zheng W, Ebbesen SH, Plafker KS, Stahlhut C, Wang VM, Wills L, Nasar A, Castillo-Martin M, Cordon-Cardo C, Wilkinson JE, Powers S, Sordella R, Altorki NK, Mittal V, Stiles BM, Plafker SM, Trotman LC.

J Cell Biol. 2017 Mar 6;216(3):641-656. doi: 10.1083/jcb.201604025. Epub 2017 Feb 13.

3.

The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants.

Miller M, Shirole N, Tian R, Pal D, Sordella R.

J Cancer Biol Res. 2016;4(4). pii: 1091. Epub 2016 Dec 23.

4.

TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions.

Shirole NH, Pal D, Kastenhuber ER, Senturk S, Boroda J, Pisterzi P, Miller M, Munoz G, Anderluh M, Ladanyi M, Lowe SW, Sordella R.

Elife. 2017 Feb 1;6. pii: e25532. doi: 10.7554/eLife.25532. No abstract available.

5.

TGF-β reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells.

Pal D, Pertot A, Shirole NH, Yao Z, Anaparthy N, Garvin T, Cox H, Chang K, Rollins F, Kendall J, Edwards L, Singh VA, Stone GC, Schatz MC, Hicks J, Hannon GJ, Sordella R.

Elife. 2017 Jan 16;6. pii: e21615. doi: 10.7554/eLife.21615.

6.

TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions.

Shirole NH, Pal D, Kastenhuber ER, Senturk S, Boroda J, Pisterzi P, Miller M, Munoz G, Anderluh M, Ladanyi M, Lowe SW, Sordella R.

Elife. 2016 Oct 19;5. pii: e17929. doi: 10.7554/eLife.17929. Erratum in: Elife. 2017 Feb 01;6:.

7.

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.

Li J, Sordella R, Powers S.

Sci Rep. 2016 Jun 15;6:27891. doi: 10.1038/srep27891.

8.

MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.

Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, Wang VM, Senturk S, Fellmann C, Ding D, Beinortas T, Kleinman D, Chen M, Sordella R, Wilkinson JE, Castillo-Martin M, Cordon-Cardo C, Robinson BD, Trotman LC.

Cancer Discov. 2015 Jun;5(6):636-51. doi: 10.1158/2159-8290.CD-14-1113. Epub 2015 Mar 31.

9.

p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state.

Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh AM, Nemajerova A, Lazzara MJ, Altorki NK, Krainer A, Moll UM, Lowe SW, Cartegni L, Sordella R.

Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3287-96. doi: 10.1073/pnas.1321640111. Epub 2014 Jul 29.

10.

TAp73 is essential for germ cell adhesion and maturation in testis.

Holembowski L, Kramer D, Riedel D, Sordella R, Nemajerova A, Dobbelstein M, Moll UM.

J Cell Biol. 2014 Mar 31;204(7):1173-90. doi: 10.1083/jcb.201306066. Epub 2014 Mar 24.

11.

Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor.

Chaudhri VK, Salzler GG, Dick SA, Buckman MS, Sordella R, Karoly ED, Mohney R, Stiles BM, Elemento O, Altorki NK, McGraw TE.

Mol Cancer Res. 2013 Jun;11(6):579-92. doi: 10.1158/1541-7786.MCR-12-0437-T. Epub 2013 Mar 8.

12.

Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays.

Kani K, Sordella R, Mallick P.

Methods Mol Biol. 2012;795:233-53. doi: 10.1007/978-1-61779-337-0_16.

PMID:
21960227
13.

A rapid and scalable system for studying gene function in mice using conditional RNA interference.

Premsrirut PK, Dow LE, Kim SY, Camiolo M, Malone CD, Miething C, Scuoppo C, Zuber J, Dickins RA, Kogan SC, Shroyer KR, Sordella R, Hannon GJ, Lowe SW.

Cell. 2011 Apr 1;145(1):145-58. doi: 10.1016/j.cell.2011.03.012.

14.

Towards patient-based cancer therapeutics.

Cancer Target Discovery and Development Network, Schreiber SL, Shamji AF, Clemons PA, Hon C, Koehler AN, Munoz B, Palmer M, Stern AM, Wagner BK, Powers S, Lowe SW, Guo X, Krasnitz A, Sawey ET, Sordella R, Stein L, Trotman LC, Califano A, Dalla-Favera R, Ferrando A, Iavarone A, Pasqualucci L, Silva J, Stockwell BR, Hahn WC, Chin L, DePinho RA, Boehm JS, Gopal S, Huang A, Root DE, Weir BA, Gerhard DS, Zenklusen JC, Roth MG, White MA, Minna JD, MacMillan JB, Posner BA.

Nat Biotechnol. 2010 Sep;28(9):904-6. doi: 10.1038/nbt0910-904. No abstract available.

15.

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.

Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, Kenner L, Sordella R.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15535-40. doi: 10.1073/pnas.1009472107. Epub 2010 Aug 16.

16.

Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.

Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, Mitsudomi T, Haber DA.

Clin Cancer Res. 2008 Jul 1;14(13):4079-84. doi: 10.1158/1078-0432.CCR-07-5030.

17.

DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma.

Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, Singer S, Kuehnel F, Wigler M, Powers S, Zender L, Lowe SW.

Genes Dev. 2008 Jun 1;22(11):1439-44. doi: 10.1101/gad.1672608.

18.

Dialogue between RhoA/ROCK and members of the Par complex in cell polarity.

Sordella R, Van Aelst L.

Dev Cell. 2008 Feb;14(2):150-2. doi: 10.1016/j.devcel.2008.01.015.

19.

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.

McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.

Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. Epub 2007 Dec 6.

20.

Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.

Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, Anderson KS, Settleman J.

Cancer Res. 2007 Mar 1;67(5):2325-30.

21.

Distinct but overlapping functions for the closely related p190 RhoGAPs in neural development.

Matheson SF, Hu KQ, Brouns MR, Sordella R, VanderHeide JD, Settleman J.

Dev Neurosci. 2006;28(6):538-50.

PMID:
17028431
22.

Driving actin dynamics under the influence of alcohol.

Sordella R, Van Aelst L.

Cell. 2006 Oct 6;127(1):37-9.

23.

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.

Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J.

Cold Spring Harb Symp Quant Biol. 2005;70:419-26. Review.

PMID:
16869779
24.

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.

Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21. Epub 2006 Feb 6.

25.

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA.

Nat Genet. 2005 Dec;37(12):1315-6. Epub 2005 Oct 30.

PMID:
16258541
26.

p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling.

Barberis D, Casazza A, Sordella R, Corso S, Artigiani S, Settleman J, Comoglio PM, Tamagnone L.

J Cell Sci. 2005 Oct 15;118(Pt 20):4689-700. Epub 2005 Sep 27.

27.

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70. Epub 2005 May 16.

28.

An FF domain-dependent protein interaction mediates a signaling pathway for growth factor-induced gene expression.

Jiang W, Sordella R, Chen GC, Hakre S, Roy AL, Settleman J.

Mol Cell. 2005 Jan 7;17(1):23-35.

29.

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.

Sordella R, Bell DW, Haber DA, Settleman J.

Science. 2004 Aug 20;305(5687):1163-7. Epub 2004 Jul 29.

30.

SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway.

Kontaridis MI, Eminaga S, Fornaro M, Zito CI, Sordella R, Settleman J, Bennett AM.

Mol Cell Biol. 2004 Jun;24(12):5340-52.

31.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

32.

Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis.

Sordella R, Jiang W, Chen GC, Curto M, Settleman J.

Cell. 2003 Apr 18;113(2):147-58. Erratum in: Cell. 2003 May 16;113(4):547.

33.

DOCK4, a GTPase activator, is disrupted during tumorigenesis.

Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, Reynolds P, Bell DW, Lake R, van den Heuvel S, Settleman J, Haber DA.

Cell. 2003 Mar 7;112(5):673-84.

34.

Modulation of CREB activity by the Rho GTPase regulates cell and organism size during mouse embryonic development.

Sordella R, Classon M, Hu KQ, Matheson SF, Brouns MR, Fine B, Zhang L, Takami H, Yamada Y, Settleman J.

Dev Cell. 2002 May;2(5):553-65.

35.

Protein interaction mapping in C. elegans using proteins involved in vulval development.

Walhout AJ, Sordella R, Lu X, Hartley JL, Temple GF, Brasch MA, Thierry-Mieg N, Vidal M.

Science. 2000 Jan 7;287(5450):116-22.

Supplemental Content

Loading ...
Support Center